Last updated on May 2018

Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia


Brief description of study

This dose-escalating phase I trial assesses for the first time the safety, the side effects and the harmlessness, as well as the therapeutical benefit of the new study drug GEM333 in patients with acute myeloid leukemia (AML). This AML was relapsed after previous therapy or was refractory to the standard therapy.

Clinical Study Identifier: NCT03516760

Contact Investigators or Research Sites near you

Start Over

Götz-Ulrich Grigoleit, MD

Universit tsklinikum W rzburg
Würzburg, Germany
  Connect »

Martin Wermke, MD

Universit tsklinikum Dresden
Dresden, Germany
  Connect »